Abstract
Meeting abstracts The prognosis is poor for patients with cHL who relapse after autologous stem-cell transplant (auto-SCT) or progress after brentuximab vedotin (BV) therapy. cHL frequently harbors genetic amplification at 9p24.1, which leads to overexpression of PD-L1 and PD-L2 on the tumor cell
Highlights
The prognosis is poor for patients with cHL who relapse after autologous stem-cell transplant or progress after brentuximab vedotin (BV) therapy. cHL frequently harbors genetic amplification at 9p24.1, which leads to overexpression of PD-L1 and PD-L2 on the tumor cell surface
This suggests that cHL may have a genetically determined dependence on the PD-1 pathway for survival
Pembrolizumab is a humanized monoclonal antibody against PD-1 that is designed to block the interaction of PD-1 with its ligands PD-L1 and PD-L2
Summary
Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087. Robert Chen1*, Phillippe Armand, Michelle A Fanale, Vincent Ribrag, Pier Luigi Zinzani, Alejandro D Ricart, Seth Thompson, Arun Balakumaran, Daniel Molin, Margaret A Shipp, Craig H Moskowitz. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
